Brief: Quantum Genomics Updates On Impact Of COVID-19 On Clinical Research Activities
07/04/2020 18:13
April 7 (Reuters) - QUANTUM GENOMICS SA ALQGC.PA :
* PROVIDES UPDATE ON IMPACT OF COVID-19 HEALTH CRISIS ON
CLINICAL
RESEARCH ACTIVITIES
* COMPANY IMPLEMENTED MITIGATION PLANS TO SECURE SUPPLY OF
RAW
MATERIALS AND PRODUCTION OF FIRIBASTAT, WHICH IS MADE IN FRANCE
* ALL EMPLOYEES ARE THEREFORE ABLE TO CONTINUE WORKING ON
DEVELOPMENT PROJECTS
Source text for Eikon: ID:nGNXTRSBY
Further company coverage: ALQGC.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study